# A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

> **NCT03057366** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Advanced Solid Tumors, Neoplasms, Advanced Solid

## Interventions

- **DRUG:** Pevonedistat
- **DRUG:** [14C]-Pevonedistat
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03057366
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-11
- **Primary completion:** 2018-02-08
- **Final completion:** 2018-11-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057366, "A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03057366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*